Pseudomonas aeruginosa: Infections and novel approaches to treatment "Knowing the enemy" the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment
- PMID: 38073886
- PMCID: PMC10699684
- DOI: 10.1016/j.imj.2023.05.003
Pseudomonas aeruginosa: Infections and novel approaches to treatment "Knowing the enemy" the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment
Abstract
Pseudomonas aeruginosa is an aerobic Gram-negative rod-shaped bacterium with a comparatively large genome and an impressive genetic capability allowing it to grow in a variety of environments and tolerate a wide range of physical conditions. This biological flexibility enables the P. aeruginosa to cause a broad range of infections in patients with serious underlying medical conditions, and to be a principal cause of health care associated infection worldwide. The clinical manifestations of P. aeruginosa include mostly health care associated infections and community-acquired infections. P. aeruginosa possesses an array of virulence factors that counteract host defence mechanisms. It can directly damage host tissue while utilizing high levels of intrinsic and acquired antimicrobial resistance mechanisms to counter most classes of antibiotics. P. aeruginosa co-regulates multiple resistance mechanisms by perpetually moving targets poses a significant therapeutic challenge. Thus, there is an urgent need for novel approaches in the development of anti-Pseudomonas agents. Here we review the principal infections caused by P. aeruginosa and we discuss novel therapeutic options to tackle antibiotic resistance and treatment of P. aeruginosa infections that may be further developed for clinical practice.
Keywords: Antibiotics; Bacteriophages; Immunotherapy; Infections; Novel Approaches; Pseudomonas; Resistance; Vaccines.
© 2023 The Author(s).
Figures
Similar articles
-
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients.Microbiol Spectr. 2023 Feb 14;11(1):e0443722. doi: 10.1128/spectrum.04437-22. Epub 2023 Jan 24. Microbiol Spectr. 2023. PMID: 36692293 Free PMC article.
-
Anti-Pseudomonas aeruginosa Vaccines and Therapies: An Assessment of Clinical Trials.Microorganisms. 2023 Mar 31;11(4):916. doi: 10.3390/microorganisms11040916. Microorganisms. 2023. PMID: 37110338 Free PMC article. Review.
-
[Chinese expert consensus on the management of lower respiratory tract infections of Pseudomonas aeruginosa in adults(2022)].Zhonghua Jie He He Hu Xi Za Zhi. 2022 Aug 12;45(8):739-752. doi: 10.3760/cma.j.cn112147-20220407-00290. Zhonghua Jie He He Hu Xi Za Zhi. 2022. PMID: 35927044 Chinese.
-
Pseudomonas aeruginosa: new insights into pathogenesis and host defenses.Pathog Dis. 2013 Apr;67(3):159-73. doi: 10.1111/2049-632X.12033. Epub 2013 Mar 15. Pathog Dis. 2013. PMID: 23620179 Review.
-
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies.Biotechnol Adv. 2019 Jan-Feb;37(1):177-192. doi: 10.1016/j.biotechadv.2018.11.013. Epub 2018 Nov 27. Biotechnol Adv. 2019. PMID: 30500353 Review.
Cited by
-
Clinical Characteristics and Predictors of Mortality of Patients with Post-Neurosurgical Meningitis-A 900-Cases Cohort Study.Infect Drug Resist. 2024 Nov 5;17:4853-4863. doi: 10.2147/IDR.S491379. eCollection 2024. Infect Drug Resist. 2024. PMID: 39524980 Free PMC article.
-
Inhaled CD24-Enriched Exosomes (EXO-CD24) as a Novel Immune Modulator in Respiratory Disease.Int J Mol Sci. 2023 Dec 20;25(1):77. doi: 10.3390/ijms25010077. Int J Mol Sci. 2023. PMID: 38203250 Free PMC article.
-
Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University.Sci Rep. 2024 Feb 1;14(1):2657. doi: 10.1038/s41598-024-52192-3. Sci Rep. 2024. PMID: 38302552 Free PMC article.
-
Pseudomonas aeruginosa Isolates from Water Samples of the Gulf of Mexico Show Similar Virulence Properties but Different Antibiotic Susceptibility Profiles than Clinical Isolates.Int J Microbiol. 2024 May 16;2024:6959403. doi: 10.1155/2024/6959403. eCollection 2024. Int J Microbiol. 2024. PMID: 38784405 Free PMC article.
-
Capsid structure of bacteriophage ΦKZ provides insights into assembly and stabilization of jumbo phages.Nat Commun. 2024 Aug 2;15(1):6551. doi: 10.1038/s41467-024-50811-1. Nat Commun. 2024. PMID: 39095371 Free PMC article.
References
-
- Wu W., Jin Y., Bai F., et al. In: Molecular Medical Microbiology. 2nd ed. Tang T.W., Sussman M., Liu D., Poxton I., Schwartzman J., editors. Academic Press; Cambridge, MA, USA: 2015. Chapter 41—pseudomonas aeruginosa; pp. 753–767. - DOI
-
- El-Fouly M.Z., Sharaf A.M., Shahin A.A.M, et al. Biosynthesis of pyocyanin pigment by Pseudomonas aeruginosa. J. Radiat. Res. Appl. Sci. 2015;8(1):36–48. doi: 10.1016/j.jrras.2014.10.007. - DOI
-
- Brady M.T., Leber A. Principles and Practice of Pediatric Infectious Diseases. Elsevier; 2018. Less Commonly Encountered Nonenteric Gram-Negative bacilli; pp. 855–859. - DOI
Publication types
LinkOut - more resources
Full Text Sources